Preliminary report of biological basis of sensitivity to the effects of cannabis on psychosis: AKT1 and DAT1 genotype modulates the effects of d-9-tetrahydrocannabinol on midbrain and striatal function Cannabis use can induce acute psychotic symptoms 1 and increase the long-term risk of schizophrenia, 2 but there is a marked interindividual variability in the susceptibility to these effects. The latter is thought to have a genetic basis, but it is unclear which particular genes are responsible. Here we show that the acute psychotogenic effects of cannabis are moderated by two genes that code for proteins that influence dopamine metabolism, and modulate the effects of the drug on midbrain and striatal function.
The effects of cannabis on psychosis are mediated by its constituent d-9-tetrahydrocannabinol (d-9-THC).
1 Induction of psychotic symptoms by d-9-THC is related to its effect on the striatum, 1 a brain region rich in dopaminergic terminals. Direct measurement of the effects of d-9-THC on central dopaminergic transmission in man have been less clear, with two studies showing evidence of an increase in the striatum 3 and extrastriatal regions, 4 and another showing no effect in the striatum. 5 However, animal studies (reviewed in ref. 6 ) have unequivocally demonstrated an effect of d-9-THC on central dopaminergic transmission. The marked interindividual variation in the psychotic effects of cannabis may therefore reflect differences in genes that influence the transmission or metabolism of brain dopamine. We tested this hypothesis by examining the effects of variation in the genes for the dopamine transporter (DAT1, which removes dopamine from central synapses 7 ) and the protein kinase B (AKT1, an integral component of the dopamine signaling cascade 8 ) on the symptomatic and neurophysiological response to d-9-THC. The human DAT1 gene has a polymorphic 40 bp variable number of tandem repeats (VNTR) in the 3 0 untranslated region (UTR), with several alleles ranging from 3 to 11 copies of the 40-bp repeats, the 9-repeat and 10-repeat alleles being the most common. The DAT1 3 0 UTR VNTR modulates activity in the striatum 7, 9 and midbrain, 9 and its 9-repeat allele is associated with higher synaptic dopamine levels than the 10-repeat counterpart. 10 AKT1 has recently been implicated in mediating the effects of cannabis on psychosis, 11 and variants of both genes have been linked with schizophrenia in genetic association studies. [12] [13] [14] Employing an established repeated measures, placebo-controlled, within-subject design 1 (Supplementary Material), we examined the acute effects of d-9-THC on psychotic symptoms and regional brain activation in 35 healthy volunteers who had minimal previous cannabis use and had been genotyped for the DAT1 3 0 UTR VNTR and the AKT1 rs1130233 polymorphisms. Symptomatic effects of d-9-THC were recorded using standard psychopathological instruments. The blood oxygen level dependent response was measured while subjects performed a verbal learning task 1 inside a magnetic resonance imaging scanner.
There was a main effect of DAT1 genotype (F 1,31 = 7.46, P = 0.01; 9-repeat carriers > 10-repeat homozygotes) and a trend for a main effect of AKT1 genotype (F 1,31 = 3.42, P = 0.07; G homozygotes > heterozygotes) on the increase in psychotic symptoms induced by d-9-THC. There was also an interaction (F 1,31 = 4.49, P = 0.04) between the effects of the DAT1 and AKT1 genotypes on the symptomatic effect of d-9-THC; the increase in symptoms was greater in individuals who were G homozygotes of AKT1 rs1130233 and also carriers of the 9-repeat allele of the DAT1 3 0 UTR VNTR (hereafter referred to as GG/9-repeat carrier; n = 7), relative to those that were not (hereafter referred to as REST; n = 28) (P < 0.001; post-hoc testing; Figure 1a and Supplementary Figures 1 and 2 ; Supplementary  Tables 1-6 ).
This was associated with an interaction between the effects of DAT1 and AKT1 genotype and of d-9-THC on activation in the striatum during encoding, and in the midbrain during recall (Supplementary Material). During encoding, following placebo, individuals who were G homozygotes of AKT1 and carriers of the 9-repeat allele (DAT1 3 0 UTR VNTR) showed strong striatal activation, whereas there was a little response in the REST (Figure 1b) . d-9-THC markedly attenuated the striatal activation in GG/ 9-repeat carrier individuals, but had a minimal effect in the REST group. Similarly, during the recall condition, following placebo, subjects who were homozygotes for the G allele of AKT1 and carriers of the 9-repeat allele for the DAT1 3 0 UTR VNTR showed strong activation in the midbrain, whereas there was only a modest response in the REST (Figure 1c) . Administration of d-9-THC led to deactivation in the midbrain in GG/9-repeat carrier individuals, but had little effect on the response in the REST group. This interaction at the neurophysiological level was not secondary to effects at the behavioral level, as there were no significant interactions between d-9-THC and genotype on task performance.
To confirm the role of the striatum and midbrain in mediating the psychotic effects of d-9-THC, we examined the relationship between its effect on activation in these regions and its effect on psychotic symptoms. In both areas, there was a correlation between the neurophysiological effects of d-9-THC and the severity of psychotic symptoms it induced: the more d-9-THC attenuated striatal and midbrain activation, the greater the severity of the psychotic symptoms (Figures 1d and e) .
While these results should be considered as preliminary and need independent replication, they are consistent with the effects of the DAT1 3 0 UTR VNTR on midbrain and striatal activity 7, 9 and the activation of striatal AKT1
15 by d-9-THC. They are also consistent with independent epidemiological 11, 16 and experimental 17, 18 evidence that heritable variations in dopamine neurotransmission affecting the signaling cascade or synaptic availability of dopamine moderate sensitivity to the acute 17, 18 and longterm 11, 16 effects of cannabis on psychosis and extend this further by describing how such an effect may be mediated in the brain. Together, they suggest that individuals carrying the risk variants of either the DAT1 3 0 UTR VNTR or the AKT1 rs130233 polymorphisms have an increased sensitivity to the psychotic effects of d-9-THC, but that this is especially increased in subjects who carry both these variants. Furthermore, this effect involves an alteration in the neural response to d-9-THC in the dopamine-rich regions of striatum and midbrain, consistent with independent evidence that the psychotic effects of cannabis are mediated by dopamine.
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The authors declare no conflict of interest. The single nucleotide polymorphism (SNP) rs1344706 in the ZNF804A gene was the first SNP to reach unequivocal genome-wide significance for schizophrenia, but little is known about how it confers susceptibility. Here, we looked for neuroanatomical correlates of rs1344706, and of other SNPs across the gene, in a large structural MRI data set of healthy young adults, using brain volumetry and voxel-based morphometry (VBM). Neither rs1344706 nor the other SNPs, individually or in combination, affected any volumetric or VBM parameter. As such, the association of ZNF804A with psychosis seems unlikely to be mediated through an influence of rs1344706 or any other SNP on macroscopic brain structure.
Schizophrenia and bipolar disorder are highly heritable disorders. Data from genome-wide association studies (GWAS) provide compelling evidence for association to the ZNF804A (zinc finger protein 804A) gene, at chromosome 2q32.1. Association to schizophrenia was originally reported in 2008, 1 and a recent meta-analysis of > 21 000 cases and 38 000 controls found an odds ratio (OR) of 1.10, P = 2.5 Â 10 À11 for schizophrenia, and OR 1.11, P = 4 Â 10 À13 for schizophrenia and bipolar disorder combined. 2 The genetic signal arises predominantly from a single, intragenic SNP, rs1344706 3 or possibly a haplotype that includes it. 2 The roles of ZNF804A and the functional correlates of rs1344706 are unclear, although the latter is predicted to create a transcription factor-binding site and to affect gene expression of ZNF804A. 4 Several studies have used neuroimaging to examine whether rs1344706 impacts upon brain structure. Lencz et al. 5 showed in 39 healthy volunteers that carriers of the risk allele (A) of rs1344706 had significantly larger total white matter but reduced gray
